Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Celecoxib/famciclovir - Virios Therapeutics

Drug Profile

Celecoxib/famciclovir - Virios Therapeutics

Alternative Names: Famciclovir/celecoxib; IMC-1

Latest Information Update: 28 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Innovative Med Concepts
  • Developer Virios Therapeutics
  • Class Antimigraines; Antineoplastics; Antipyretics; Antirheumatics; Antivirals; Irritable bowel syndrome therapies; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Nucleosides; Purines; Pyrazoles; Small molecules; Sulfonamides
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors; DNA-directed DNA polymerase inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Fibromyalgia
  • No development reported Chronic fatigue syndrome; Irritable bowel syndrome

Most Recent Events

  • 28 Apr 2024 No recent reports of development identified for phase-I development in Chronic-fatigue-syndrome in Unknown (PO)
  • 28 Apr 2024 No recent reports of development identified for phase-I development in Irritable-bowel-syndrome in Unknown (PO)
  • 04 Mar 2024 Celecoxib/famciclovir - Virios Therapeutics is available for licensing as of 29 Feb 2024. https://www.virios.com/#comp-ig277xvm1
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top